Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residents of one of the participating LTC sites~* 65 years or older at the time of consent~* require assistance in two or more Instrumental Activities of Daily Living and/or one or more Activities of Daily Living as identified by facility staff~Exclusion Criteria:~* Age less than 65 years~* Life expectancy less than 6 months~* History of allergic reaction to influenza vaccine, its components, or eggs~* History of severe allergic reaction to latex~* History of Guillian-Barre Syndrome~* Actively undergoing chemotherapy~* Actively undergoing radiation therapy~* Use of prednisone (or other steroid) at prednisone-equivalent dosages of 10mg or higher within the past 14 days~* Serious current immunosuppression or immunosuppression expected in the next 6 weeks~* Any condition that, in the opinion of the investigator,might interfere with the evaluation of study objectives

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- High Dose Inactivated Influenza Vaccine (Type: ACTIVE_COMPARATOR): For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
- Standard Dose Inactivated Influenza Vaccine (Type: ACTIVE_COMPARATOR): For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin

Based on this trial design, predict the completion outcome and termination type (if applicable).